BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

CTI Molecular Imaging, Inc. (CTMI) Announces Date Of First Quarter Earnings Release And Conference Call


10/19/2005 5:12:32 PM

KNOXVILLE, Tenn., Jan. 21 /PRNewswire-FirstCall/ -- CTI Molecular Imaging, Inc. , announced today that it will release its earnings results for the fiscal first quarter ended December 31, 2004, before the market opens on Tuesday, February 1, 2005.

The company will host a conference call on that date to discuss these results at 9:00 am EST. The dial-in number for the earnings call is (706) 643-3432. A replay of the call will be available for one week until February 8. The replay number is (800) 642-1687 and the reservation number is 3583738.

A simultaneous webcast of the call will be accessible via the Internet at http://www.ctimi.com/ in the investor relations section. A replay of the webcast will also be archived on this site.

About CTI Molecular Imaging:

CTI Molecular Imaging, Inc. is a leading supplier of products and services for positron emission tomography (PET), a diagnostic imaging technology used in the detection and treatment of cancer, neurological disorders and cardiac disease. Additional information is available at: http://www.ctimi.com/ .

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding CTI Molecular Imaging, Inc.'s business that are not historical facts are "forward-looking statements" that involve risks and uncertainties. Further information regarding such risks and uncertainties and other factors that could adversely affect CTI or cause actual results to differ materially from those anticipated in forward- looking statements are included in CTI's Annual Report on Form 10-K for the fiscal year ended September 30, 2004 and in other reports CTI files with the SEC. CTI undertakes no obligation to update or revise any forward-looking statements.

CTI Molecular Imaging, Inc.

CONTACT: David Gill of CTI Molecular Imaging, Inc., +1-865-218-2000



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES